P. Ochoa

Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple

D. Fantl, N. Schütz, P. Ochoa, 2020 .

Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance‐related lesions in Latin America

D. Fantl, P. Ochoa, C. Shanley, 2019, Nephrology.

Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple

D. Fantl, P. Ochoa, P. Duarte, 2021, Expert review of hematology.

Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

M. Roa, C. Sossa, G. Ruiz-Argüelles, 2020, Leukemia & lymphoma.

Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series

P. Ochoa, G. Remaggi, G. Garate, 2022, The American journal of case reports.

Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group

M. Roa, D. Fantl, P. Ochoa, 2022, Leukemia & lymphoma.